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With the rapid development of industry and farm, fungi contamination widely exists 
in occupational environment. Inhalation of fungi-contaminated organic dust results in 
hypersensitivity pneumonitis. 1,3-β-Glucan is a major cell wall component of fungus and 
is considered as a biomarker of fungi exposure. Current studies showed that 1,3-β-glu-
can exposure induced lung inflammation, which involved uncontrolled T helper (Th) cell 
immune responses, such as Th1, Th2, Th17, and regulatory T  cell (Treg). A recently 
identified IL-10-producing B cells (B10) was reported in regulating immune homeostasis. 
However, its regulatory role in hypersensitivity pneumonitis is still subject to debate. In 
our study, we comprehensively investigated the role of B10 and the relationship between 
B10 and Treg in 1,3-β-glucan-induced lung inflammation. Mice with insufficient B10 
exhibited more inflammatory cells accumulation and severer pathological inflammatory 
changes. Insufficient B10 led to increasing Th1, Th2, and Th17 responses and restricted 
Treg function. Depletion of Treg before the onset of inflammation could suppress B10. 
Whereas, Treg depletion only at the late stage of inflammation failed to affect B10. Our 
study demonstrated that insufficient B10 aggravated the lung inflammation mediated 
by dynamic shifts in Th immune responses after 1,3-β-glucan exposure. The regulatory 
function of B10 on Th immune responses might be associated with Treg and IL-10. Treg 
could only interact with B10 at an early stage.
Keywords: regulatory B cells, T helper immune responses, 1,3-β-glucan, lung inflammation, occupational disease
inTrODUcTiOn
Organic dust exists widely in the occupational environment, such as farm and industries that process-
ing hay, paper, fur, or household waste (1, 2). Inhalation of organic dust induces acute or chronic lung 
inflammation, named as hypersensitivity pneumonitis. And its latent period ranges from several 
hours to several months (3). Although it is curable in some cases, granulomatous inflammation 
may result in irreversible fibrosis (4). The etiology of hypersensitivity pneumonitis in organic dust 
working environments includes kinds of microorganism and animal antigens. Epidemiologic study 
demonstrates that fungi concentration is much higher in jute, fur, or silk-processing workshops, 
which seriously damage the workers’ health in occupational environment. Organic dust exposure 
is often characterized by high levels of viable fungi and fungal spores, which drew considerable 
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attention (5, 6). 1,3-β-Glucan is a major cell wall component of 
fungi and is considered as a biomarker of fungi exposure (7).
Existing evidence supports an obvious relationship between 
the airborne level of 1,3-β-glucan and the respiratory symptom 
(4). Abundant immune cells are reported to be involved in 
1,3-β-glucan-induced lung inflammation, including neutrophils, 
macrophages, and lymphocytes especially. This suggests that both 
innate and adaptive immune responses took part in 1,3-β-glucan-
induced lung inflammation. Patients with hypersensitivity pneu-
monitis exhibit high percentage of lymphocytes in peripheral 
blood, which indicates a crucial role of lymphocytes in the devel-
opment of hypersensitivity pneumonitis (8). We have previously 
showed that multiple CD4+ T lymphocyte responses dominated 
in different stages after 1,3-β-glucan exposure, including T helper 
(Th)1, Th2, Th17, and regulatory T cell (Treg) (9, 10). Exogenous 
1,3-β-glucan induces numerous kinds of inflammatory cytokines 
and chemokine through NF-kB and NLRP3 signal pathways (11, 
12). And then activates the Th1 response and Th2 response in 
sequence. Th17 response also participates in the initial acute 
inflammation. Besides, we have previously demonstrated that 
Treg impacted on the Th1/Th2 immune responses skewed to 
Th1 predominance. Treg depletion modulates the process of 
1,3-β-glucan-induced lung inflammation and the later fibrosis 
pathological change (9).
Besides these classical T cell subtypes, a novel regulatory B cell 
is reported to be capable of controlling autoimmune disease, aller-
gic disease, and tumorigenesis (13–15). B cell depletion increases 
asthma-like airway inflammation in mice (16, 17). Activation 
of CD19+CD1dhi B  cells suppresses allergic lung inflammation 
(18–20). CD19+CD24hiCD38hi B cells possess regulatory function 
in pneumonia patients and are associated with later development 
of its complication (21). Although there is various phenotypes for 
regulatory B cells, such as CD1dhiCD5+, CD21+CD23+, or TIM-
1+, several reports describe an IL-10-producing B cells (B10) in 
controlling chronic intestinal inflammation and experimental 
autoimmune encephalomyelitis (22, 23). Therefore, CD19 and 
IL-10 are used as markers for B10 (24). B10 could modulate Th 
immune responses by affecting the secretion of inflammatory 
cytokines, such as IFN-γ, IL-12, and IL-17 (19, 25). Study in vitro 
demonstrates that IL-10-overexpressing B  cells were able to 
suppress the secretion of inflammatory cytokines, the matura-
tion of dendritic cells, and the antigen-specific proliferation 
(26). Transfer of antigen-specific IL-10-depleted splenic B cells 
restores experimental ovalbumin (OVA)-induced allergic airway 
inflammation (16). CD22 was dominantly expressed on B cells 
and considered to play an important role in regulating B  cells 
by binding to its ligand. Preferential depletion of B10 by using 
anti-CD22 antibody could amplify the focal and systematic 
inflammation (27, 28). However, the regulatory mechanism of 
B10 in lung inflammation is still subject to debate. Some believe 
that IL-10 is instrumental for B10s suppressive effect (16, 29). 
And Treg is reported to help the regulatory function of B10 
(20, 30). However, other evidence shows the regulatory role of B10 
is Treg-independent (31, 32). Whether the regulatory function 
of B10 relies on Treg is still dubious. The regulatory mechanism 
of B10 in 1,3-β-glucan-induced lung inflammation is not well 
understood.
In this study, we investigated the role of B10 during the 
development of 1,3-β-glucan-induced lung inflammation. The 
regulatory effect of B10 on 1,3-β-glucan-induced Th responses 
was investigated, and the reciprocal relationship between B10 and 
Treg was discussed. We concluded that insufficient B10 aggra-
vated the lung inflammation via promoting different Th immune 
responses during different stages after 1,3-β-glucan exposure. The 
regulatory function of B10 on Th immune responses might be 
associated with Treg and IL-10. Treg could only interact with B10 
at an early stage.
aniMals anD MeThODs
animals
Healthy female C57BL/6 mice at 6–8 weeks age were purchased 
from SLAC Laboratory Animal Co. Ltd. (Shanghai, China). All 
animals were housed in a specific-pathogen-free environment 
and maintained on standard mouse chow at an environmental 
temperature of 24 ± 1°C, with 12 h light/12 h dark cycles, and 
water ad libitum.
1,3-β-glucan exposure
Eighty-four female mice were randomly allocated into five groups 
according to weight as follows: saline group, saline + anti-CD22 
group, glucan group, glucan + anti-CD22 group, and glucan + anti-
CD25 group. Zymosan A (1,3-β-glucan) from Saccharomyces 
cerevisiae (Z4250), purchased from Sigma-Aldrich Inc. (St. Louis, 
MO, USA), was dissolved in sterile saline to a final concentration 
of 6 mg/ml. Female mice were anesthetized with intraperitoneal 
injection of 2% pentobarbital sodium (45 mg/kg body weight). 
Mice received 0.3 mg/50 μl zymosan solution intratracheally to 
induce lung inflammation. Control mice received 50-µl sterile 
saline at the same time.
B10/Treg Depletion
To deplete CD19+IL10+ regulatory B  cells, mice were injected 
intraperitoneally with 300 µg anti-CD22 antibody (KH2014176, 
F239, Sangon Biotech, Shanghai, China) 1 day before 1,3-β-glucan 
exposure and repeatedly treated every 7  days for continuing 
depletion (27, 28). To deplete CD4+Foxp3+ Treg, mice received 
intraperitoneal injection of 100  µg of anti-CD25 mAb (PC61; 
BioLegend, San Diego, CA, USA) as described previously (9). 
IgG1 was used as control.
Bronchoalveolar lavage
The whole experimental procedure was showed in Figure 1. In 
brief, mice were sacrificed on 1, 7, or 21 days after 1,3-β-glucan 
exposure. Bronchoalveolar lavage fluid (BALF) was obtained and 
centrifuged at 1,500 rpm for 8 min at 4°C. RBCs were lysed, and 
the BALF cell pellet was washed and resuspended in phosphate-
buffered saline (PBS). The total cell counts were determined using 
standard hematological procedures. BALF cytospin was prepared 
and stained using the Wright–Giemsa method. In brief, three 
major inflammatory cells could be observed under the optical 
microscope (200×): polymorphonuclear neutrophils, small and 
medium-sized lymphocytes, and large macrophages with visible 
FigUre 1 | schematic diagrams of the experimental design. To deplete IL-10-producing B cells, C57BL/6 mice were treated i.p. with anti-CD22 Ab on 1 day 
before 1,3-β-glucan exposure and on days 6, 13, and 20 after 1,3-β-glucan exposure for continuous depletion. Anti-CD25 Ab was applied on either 1 day before 
1,3-β-glucan exposure or on day 20 after 1,3-β-glucan exposure to deplete regulatory T cell on the two separate stages during 1,3-β-glucan-induced lung 
inflammation. Mice were sacrificed on days 1, 7, and 21. The bronchoalveolar lavage fluid (BALF), tissues, and cells were collected for the following assay.
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cytoplasm. Neutrophils, macrophages, and lymphocytes were 
identified in a population of 200 cells using standard morphologi-
cal criteria.
Pathological examination
Mice lungs were fixed in 4% paraformaldehyde–PBS. The tissue 
was embedded in paraffin and cut into 6 µm thick sections. The 
tissue sections were stained with H&E for pathological exami-
nation. In general, slides were viewed under Olympus BX51 
microscope, and photographic images of lung morphology 
were captured at 10 × 20 magnification. Lung inflammation was 
graded into four stages and scored as follows (33): 0 point—nor-
mal lung; 1 point—light inflammation, minimal inflammatory 
thickening of alveolar walls, limited to the local area involving 
<20% of lung area, and normal alveolar structure; 2 points—
medium inflammation and involving 20–50% inflammation 
of the entire lung area; 3 points—heavy inflammation, lesion 
involving >  50% of the lung area, severe structure distortion, 
monocyte infiltration into the alveolar space, and presence of 
consolidation.
isolation of hilar lymph nodes  
(hlns) and spleen cells
Hilar lymph nodes were harvested, dissected with dissection 
needles, and digested with 0.25% trypsin at 37°C for 5 min. Then, 
3% fetal bovine serum PBS was used to quench the digestion. 
Samples were centrifuged at 1,500  rpm for 8  min at 4°C. The 
HLN cell pellet was washed and resuspended in PBS. The spleen 
was removed, ground, and mechanically dissociated in cold PBS. 
After lysis of RBCs, spleen cells were washed and resuspended 
in PBS.
Flow cytometry
The HLN and spleen cells were stimulated with Leukocyte 
Activation Cocktail (BD Pharmingen, San Jose, CA, USA) and 
LPS 10  µg/ml (Sigma-Aldrich, St. Louis, MO, USA) for 5  h, 
followed by blocking with purified rat anti-mouse CD16/CD32 
(2.4G2; BD Pharmingen) for 10 min at 4°C. Cell-surface stain-
ing was performed with PerCP-Cy5.5 conjugated CD4 (RM4-5; 
BD Pharmingen) or PerCP-Cy5.5 conjugated CD19 (1D3; BD 
Pharmingen) as described previously (9). Cells were fixed and 
permeabilized using a Fixation/Permeabilization kit (eBiosci-
ence, San Diego, CA, USA) or BD Cytofix/Cytoperm™ Fixation/
Permeabilization Solution kit (BD Pharmingen) according to 
the manufacturer’s instructions. Then, cells were stained for 
20 min at 4°C with Alexa Fluor 488-conjugated IFN-γ (XMG1.2; 
BD Pharmingen), PE-conjugated IL-17A (TC11-18H10; BD 
Pharmingen), Alexa Fluor 647-conjugated Foxp3 (MF23; 
BD Pharmingen), or PE-conjugated IL-10 (JES5-16E3; BD 
Pharmingen). Stained cells were washed twice in staining buffer 
(BD Pharmingen) and resuspended in 1% paraformaldehyde–
PBS. Analysis of cell marker expression was performed using a 
FACSCanto II system (BD, Franklin Lakes, NJ, USA). Dead cells 
were gated out depending on forward scattering and side scatter-
ing. Cells were analyzed with FlowJo software.
cytomeric Bead arrays (cBa)
Secreted protein levels in BALF were examined by CBA assay 
using mouse Th1/Th2/Th17 cytokine kit (BD Pharmingen) 
following the manufacturer’s instructions. Generally, multiple 
capture beads were mixed together, including TNF-α, IL-6, 
IFN-γ, IL-4, IL-17, and IL-10. The mixed capture beads were 
cocultured with 50 µl BALF supernatant and detection reagent 
for 2 h. The beads were washed carefully and suspended. Samples 
were analyzed by FACSCanto II system (BD). Data were analyzed 
with FCAP Array software.
rna extraction and real-time rT-Pcr
Total RNA was isolated from lung homogenates using the TRIzol 
Reagent (Invitrogen, Carlsbad, CA, USA) according to the man-
ufacturer’s instructions. The RNA concentration and the A260/
A280 ratio were determined using a UV spectrophotometer.
Primers and Taqman probes were designed with Primer3,1 
and the sequences were checked by performing a BLAST 
search.2 The primer sequences were as shown in Table  1. 
PrimeScript RT kit (DRR047A, Takara, Japan) and PrimeScript 
RT-PCR kit (DRR096A, Takara, Japan) were used for real-time 
1 http://bioinfo.ut.ee/primer3-0.4.0/primer3/.
2 http://blast.ncbi.nlm.nih.gov/Blast.cgi.
TaBle 1 | The primer sequences used for real-time Pcr.
Target gene sequence
IL-6 Forward 5′–3′ CAACGATGATGCACTTGCAGA
Reverse 5′–3′ CTCCAGGTAGCTATGGTACTCCAGA
TNF-α Forward 5′–3′ ACTCCAGGCGGTGCCTATGT
Reverse 5′–3′ GTGAGGGTCTGGGCCATAGAA
IFN-γ Forward 5′–3′ AAGCGTCATTGAATCACACCTG
Reverse 5′–3′ TGACCTCAAACTTGGCAATACTC
T-bet Forward 5′–3′ TCAACCAGCACCAGACAGAGA
Reverse 5′–3′ TCCACCAAGACCACATCCAC
IL-4 Forward 5′–3′ ACGGAGATGGATGTGCCAAAC
Reverse 5′–3′ AGCACCTTGGAAGCCCTACAGA
IL-13 Forward 5′–3′ CCCCTGTGCAACGGCAGCAT
Reverse 5′–3′ GAAGGGGCCGTGGCGAAACA
GATA3 Forward 5′–3′ GGATGTAAGTCGAGGCCCAAG
Reverse 5′–3′ ATTGCAAAGGTAGTGCCCGGTA
IL-2 Forward 5′–3′ CCCAGGATGCTCACCTTCA
Reverse 5′–3′ GCAGAGGTCCAAGTTCATCTTC
IL-17a Forward 5′–3′ GCAAAAGTGAGCTCCAGAAGG
Reverse 5′–3′ TCTTCATTGCGGTGGAGAGTC
IL-23 Forward 5′–3′ ACATGCACCAGCGGGACATA
Reverse 5′–3′ CTTTGAAGATGTCAGAGTCAAGCAG
ROR-γt Forward 5′–3′ ACGGCCCTGGTTCTCATCA
Reverse 5′–3′ CCAAATTGTATTGCAGATGTTCCAC
Foxp3 Forward 5′–3′ CCCATCCCCAGGAGTCTTG
Reverse 5′–3′ ACCATGACTAGGGGCACTGTA
CTLA-4 Forward 5′–3′ TCCGGAGGTACAAAGCTCAACTG
Reverse 5′–3′ ACCATGGCTGCTAGCCAACAC
IL-10 Forward 5′–3′ GGGGCCAGTACAGCCGGGAA
Reverse 5′–3′ CTGGCTGAAGGCAGTCCGCA
TGF-β Forward 5′–3′ TGTGGAACTCTACCAGAAATATAGC
Reverse 5′–3′ GAAAGCCCTGTATTCCGTCTC
GAPDH Forward 5′–3′ CAATGTGTCCGTCGTGGATCT
Reverse 5′–3′ GTCCTCAGTGTAGCCCAAGATG
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RT-PCR analysis. The expressions of different cytokines in mice 
lung were determined using standard methodologies described 
previously (9).
statistical analyses
Data were analyzed for statistical significance using SPSS 19.0 
software. The differences between values were evaluated through 
a one-way analysis of variance followed by pair-wise comparison 
with the Student–Newman–Keuls test. P < 0.05 was considered 
statistically significant. All values are means ± SEM.
resUlTs
B10 Participated in controlling 1,3-β-
glucan-induced lung inflammation
To study the role of B10 in 1,3-β-glucan-induced lung inflam-
mation, B10 deficiency mice model was setup by injection 
of anti-CD22 antibody every 7  days. CD22 was dominantly 
expressed in B  cells and was involved in the survival and 
regulation of B10 cells. Application of anti-CD22 antibody could 
preferentially deplete B10 in mice (34). In the present study, flow 
cytometry was performed to show whether B10 was involved 
in 1,3-β-glucan-induced lung inflammation. The percentage of 
CD19+IL-10+ B cells in the HLN increased obviously on day 1 
after 1,3-β-glucan exposure (Figures 2A,B). Then, the percentage 
of CD19+IL-10+ B  cell decreased to the same level as that 
in saline group mice at day 7 and day 21. Similar result was 
observed in spleen (Figures 2C,D). The isotype staining control 
was showed in Figure 2E. Next, to demonstrate its role, a B10 
depletion mouse model was generated by anti-CD22 antibody 
injection. Compared with the glucan group, mice treated with 
anti-CD22 showed decreased percentage of CD19+IL-10+ B cell 
in both HLN and spleen on days 1, 7, and 21 after 1,3-β-glucan 
exposure. Meanwhile, anti-CD22 treatment could not influ-
ence the percentage of CD19+IL-10+ B  cell in normal saline 
control mice. Therefore, anti-CD22 treatment could abrogate 
1,3-β-glucan-induced B10 induction.
The accumulation of inflammatory cells was observed after 
1,3-β-glucan exposure. Giemsa–Wright staining was performed 
to count inflammatory cells in BALF. As showed in Figure 3, mas-
sive inflammatory cells accumulated on day 1 after 1,3-β-glucan 
exposure, including neutrophils, macrophages, and lymphocytes. 
Anti-CD22 treatment further increased the total inflammatory 
cells number in BALF on day 1 after 1,3-β-glucan exposure 
(Figure 3A). Although no significant difference of total cells was 
observed between the glucan group mice and the glucan + anti-
CD22 group mice, anti-CD22 treatment induced an apparent 
increase of neutrophils and a considerable increase of lymphocytes 
on day 7 after 1,3-β-glucan exposure (Figures 3B,D). On day 21, 
anti-CD22 treatment significantly increased the accumulation of 
macrophages in BALF compared with that in the glucan group 
mice and the saline group mice (Figure  3C). Thus, anti-CD22 
treatment led to the accumulation of more inflammatory cells in 
BALF, primarily early neutrophils, lymphocytes, and late mac-
rophages after 1,3-β-glucan exposure.
To study the impact of B10 on the pathogenesis of 
1,3-β-glucan-induced lung inflammation, the pathological 
changes of mice lung were observed after H&E staining. And the 
pathological score of lung inflammation was showed in Table 2. 
No obvious abnormalities were observed in the saline group and 
the saline + anti-CD22 group, which indicated that anti-CD22 
treatment could not induce obvious pathological changes in lung 
(Figure 4A). Mice in the glucan group showed a large infiltration 
of inflammatory cells and exhibited alveolar septal thickening 
on day 1 after 1,3-β-glucan exposure. And then, a considerably 
reduced inflammation was observed on day 7 after 1,3-β-glucan 
exposure. The inflammation in the glucan group mice almost 
recovered on day 21 after 1,3-β-glucan exposure. Compared with 
the glucan group, mice in the glucan + anti-CD22 group demon-
strated severer infiltration of inflammatory cells on day 1. Mice 
treated with anti-CD22 continuously showed the infiltration of 
inflammatory cell and thickened alveolar septal on day 7 after 
1,3-β-glucan exposure. The remission of inflammation was not 
observed in the glucan + anti-CD22 group even on day 21 after 
1,3-β-glucan exposure. Taken together, anti-CD22 treatment 
exacerbated the inflammatory pathology changes in mice lung 
after 1,3-β-glucan exposure.
To further evaluate the inflammatory changes in lung, the rep-
resentative pro-inflammatory cytokines, IL-6 and TNF-α, were 
examined by real-time PCR and CBA. 1,3-β-Glucan exposure led 
to increased expressions and secretions of both IL-6 and TNF-α 
in mice lung and BALF on day 1. The expression of TNF-α in the 
FigUre 2 | anti-cD22 treatment attenuates il-10-producing B cells (B10) induction in vivo after 1,3-β-glucan exposure. (a,B) C57BL/6 mice were 
treated i.p. with 300 µg anti-CD22 monoclonal antibody or control IgG, and the percentage of CD19+IL-10+ regulatory B cells (B10) in the hilar lymph node was 
assayed by flow cytometry. (c,D) Percentage of B10 in spleen is shown in the graph. (e) The gating strategy of B10 in flow cytometry (n = 5; *P < 0.05 compared 
with the saline group; #P < 0.05 compared with the glucan group).
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glucan + anti-CD22 group was increased significantly compared 
with that in glucan group on day 1 (Figure 4D). The secretion of 
TNF-α in the glucan + anti-CD22 group was increased signifi-
cantly on day 7 (Figure 4E). The expression and secretion of IL-6 
also got a considerable increase in glucan + anti-CD22 group mice 
compared with glucan group mice on day 1 (Figures 4B,C). The 
enhanced levels of IL-6 and TNF-α induced by anti-CD22 treat-
ment were still obvious even on day 7 after 1,3-β-glucan exposure 
compared with the glucan group. These combined results indicate 
that insufficient B10 could aggravate the lung inflammation after 
1,3-β-glucan exposure.
B10 regulated Th immune responses 
during 1,3-β-glucan-induced lung 
inflammation
According to existing studies, Th immune responses played 
crucial roles in the development of 1,3-β-glucan-induced lung 
inflammation. Th1 response was elevated at early stage, and Th2 
response became predominant at late stage. In addition, Th17 
response also took part in the inflammatory progress. To study 
whether B10 regulated 1,3-β-glucan-induced lung inflamma-
tion by affecting Th immune responses, the phenotype of CD4+ 
T lymphocyte in HLN and the levels of cytokines were checked.
As showed in Figure  5, the percentage of IFN-γ-producing 
CD4+ T  cell (Th1  cell) was increased in anti-CD22-treated 
mice at early stage (days 1 and 7) after 1,3-β-glucan exposure 
(Figures  5A,B). Anti-CD22 treatment increased the level of 
typical Th1 cytokine, IFN-γ, on day 1 after 1,3-β-glucan exposure. 
And the increase of IFN-γ in the glucan + anti-CD22 group was 
still obvious on day 7 while its level in the glucan group reduced 
to the control level (Figures  5C,D). Although its expression 
could be associated with many immune cells, T-bet was originally 
considered as the typical Th1 transcription factor, which plays 
important roles in coordinating immune response. In this study, 
the expression of T-bet was increased considerably by anti-CD22 
treatment after 1,3-β-glucan exposure (Figure  5E). These data 
suggest that insufficient B10 enhanced the Th1 response at early 
stage of lung inflammation induced by 1,3-β-glucan.
Next, the expressions of Th2 representative cytokines were 
examined by real-time PCR. In line with our previous study, 
the elevated IL-4 expression was observed at the late stage 
after 1,3-β-glucan exposure. Anti-CD22 treatment apparently 
increased its expression on day 21 compared with that in the 
glucan group (Figure  6A). Similar tendency was observed in 
the expression of IL-13. The obvious IL-13 induction did not 
appeared until day 21 after 1,3-β-glucan exposure. However, 
anti-CD22 treatment increased the expression of IL-13 earlier 
on day 1 after 1,3-β-glucan exposure and kept its level continu-
ously rising up to peak on day 21 (Figure 6B). The expression 
of typical Th2 transcription factor GATA3 increased significantly 
in the glucan +  anti-CD22 group mice compared with that in 
TaBle 2 | inflammation score in each group at days 1, 7, and 21.









Saline 0.060 ± 0.040 0.020 ± 0.013 0.030 ± 0.020
Saline + anti-CD22 0.04 ± 0.024 0.024 ± 0.019 0.028 ± 0.017
Glucan 2.120 ± 0.086* 1.520 ± 0.171* 0.920 ± 0.128*
Glucan + anti-CD22 2.840 ± 0.060*,# 2.300 ± 0.071*,# 1.720 ± 0.066*,#
The degree of inflammation was assessed by histological analysis of six random fields 
per sample (n = 5; *P < 0.05 compared with the saline group; #P < 0.05 compared 
with the glucan group).
FigUre 3 | insufficient il-10-producing B cells enhances accumulation of inflammatory cells in lung after 1,3-β-glucan exposure. (a) Total cells,  
(B) neutrophils, (c) macrophages, and (D) lymphocytes in bronchoalveolar lavage fluid were counted using Giemsa staining. The experiment was repeated twice 
(n = 5; *P < 0.05 compared between groups).
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the glucan group (Figure 6C). This indicates that insufficient B10 
elevated Th2 response at late stage of 1,3-β-glucan-induced lung 
inflammation.
Besides, Th17 response also was studied when mice were treated 
with anti-CD22 (Figure 7). Flow cytometry results demonstrated 
that the percentage of IL-17-producing CD4+ T cell (Th17 cell) 
was higher obviously in the glucan +  anti-CD22 group than 
that in the glucan group especially on day 7 after 1,3-β-glucan 
exposure (Figures  7A,B). The expressions of representative 
Th17 cytokines also confirmed the role of anti-CD22 treatment. 
The levels of both IL-17A and IL-23 were clearly higher in the 
glucan + anti-CD22 group than that in the glucan group on day 
1, so was the expression of ROR-γt, typical Th17 transcription 
factor (Figures 7C–E). These data suggest that insufficient B10 
also promoted Th17 response in 1,3-β-glucan-induced lung 
inflammation.
The Dual relationship between B10 and 
Treg in regulating 1,3-β-glucan-induced 
lung inflammation
According to our previous studies, Treg was vital for the regula-
tion of Th immune response during 1,3-β-glucan-induced lung 
inflammation. Here, we evaluated whether Treg was involved in 
B10 regulation of Th responses. Results from flow cytometry dem-
onstrated that anti-CD22-treated mice showed lower percentage 
of Treg after 1,3-β-glucan exposure than glucan group mice 
based on its isotype staining control (Figures  8A–C). And the 
expression of foxp3, typical Treg transcription factor, decreased 
obviously in the glucan + anti-CD22 group mice compared with 
that in the glucan group (Figure  8D). What’s more anti-CD22 
treatment not only reduced the number of Treg but also affected 
its functional factor CTLA-4. Real-time PCR discovered consid-
erable restricted level of CTLA-4 in anti-CD22-treated mice on 
day 1 compared with mice in the glucan group (Figure 8E). When 
1,3-β-glucan-induced lung inflammation developed into the late 
stage, anti-CD22 treatment significantly limited the increase of 
IL-10 compared with that in glucan group (Figure 8F). Besides, 
TGF-β expression also exhibited lower level in anti-CD22-treated 
mice than that in the glucan group (Figure 8G). These data sug-
gest that insufficient B10 could limit Treg and influence IL-10 
during 1,3-β-glucan-induced lung inflammation.
Considering the controversial relationship between Treg and 
B10 based on existing studies, anti-CD25 antibody was used to 
deplete Treg in mice at early or late stage separately. As showed 
in Figure 9, anti-CD25 injection depleted Treg successfully and 
FigUre 4 | insufficient il-10-producing B cells exacerbates 1,3-β-glucan-induced inflammatory response. (a) Histopathology changes in mouse lungs 
after silica instillation observed with H&E staining (×200). a1–d1, day 1; a2–d2, day 7, and a3–d3, day 21. a1–a3, saline group; b1–b3, saline + anti-CD22 group; 
c1–c3, glucan group; d1–d3, glucan + anti-CD22 group. Secretions of IL-6 (c) and TNF-α (e) in bronchoalveolar lavage fluid were evaluated by cytomeric bead 
arrays analysis (n = 3). Expressions of IL-6 (B) and TNF-α (D) in lung were assayed by real-time PCR (n = 5–6; *P < 0.05 compared with the saline group; #P < 0.05 
compared with the glucan group).
7
Liu et al. B10 Regulated β-Glucan-Induced Inflammation
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 414
reduced its functional factors, Foxp3 and CTLA-4 (Figures 9A–C). 
Treg depletion led to obviously reduced percentage of B10 in mice 
HLN (Figure 9A). Like changes caused by insufficient B10, Treg 
depletion led to increased infiltration of inflammatory cells, such 
as neutrophils and lymphocytes on day 1 after 1,3-β-glucan expo-
sure (Figure 9D). The expressions of pro-inflammatory cytokines, 
TNF-α and IL-6, increased to a variable extent after Treg depletion 
(Figures 9E,F). On the one hand, Treg-depleted mice exhibited 
higher percentage of Th1 cell on day 1 than mice in the glucan 
group (Figure 9G). The expressions of IL-2 and T-bet were also 
elevated by Treg depletion (Figures 9I,J). On the other hand, the 
percentage of Th17  cell increased significantly in Treg-depleted 
mice (Figure  9K). Levels of classical cytokines and transcript 
factor of Th17 response, IL-17A, IL-23, and ROR-γt ascended a lot 
by Treg depletion (Figures 9L–N). These data show that depleting 
Treg at the early stage could restrict 1,3-β-glucan-induced B10 
induction, which indicates a reciprocity between B10 and Treg.
At late stage of 1,3-β-glucan-induced lung inflammation, 
Treg-depleted mice exhibited differently from mice with 
insufficient B10. As showed in Figure 10, anti-CD25 injection 
successfully reduced the percentage of Treg and lowered the 
expressions of Foxp3 and CTLA-4 on day 21 after 1,3-β-glucan 
exposure (Figures  10A–C). However, Treg depletion did not 
influence the percentage of B10 (Figure  10A). There was no 
obvious difference in inflammatory cell accumulation between 
Treg-depleted mice and mice in the glucan group on day 21 after 
FigUre 6 | insufficient il-10-producing B cells increases the Th2 response at the late stage of 1,3-β-glucan-induced lung inflammation. Expressions 
of typical Th2 cytokine IL-4 (a), IL-13 (B), and its typical transcription factor GATA3 (c) were assayed by real-time PCR (n = 5–6; *P < 0.05 compared with the 
saline group; #P < 0.05 compared with the glucan group).
FigUre 5 | insufficient il-10-producing B cells promotes the Th1 response during 1,3-β-glucan-induced lung inflammation. (a,B) Percentage of 
CD4+IFN-γ+ Th1 cells in the hilar lymph node was assayed by flow cytometry. Secretion of typical Th1 cytokine IFN-γ (D) was assayed by cytomeric bead arrays 
(n = 3). Expression of typical Th1 cytokine IFN-γ (c) and its typical transcription factor T-bet (e) were assayed by real-time PCR (n = 5–6; *P < 0.05 compared with 
the saline group; #P < 0.05 compared with the glucan group).
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1,3-β-glucan exposure (Figure 10F). In addition, the expression 
and secretion of IL-13 decreased apparently by Treg depletion at 
late stage of lung inflammation (Figures 10G,H). Although B10 
was not influenced by Treg depletion, the level of IL-10 decreased 
significantly in mice with anti-CD25 injection compared with 
that in the glucan group (Figures 10D,E). These data indicate 
that depleting Treg at late stage of 1,3-β-glucan-induced lung 
inflammation was not able to affect B10.
DiscUssiOn
The regulatory role of B  cells was not identified until recently 
(35). Studies showed that B cells participated in regulating several 
T  cell-associated diseases, such as inflammation, autoimmune 
disease, and tumorigenesis (36). And their diverse phenotypes 
were associated with CD1d, CD5, TIM-1, CD38, and CD24 cell-
surface markers in mice and humans. However, none of these 
markers uniquely defined all IL-10-producing B  cells (B10), 
which were reported to participate in chronic inflammation and 
allergic disease (14, 27, 37). Thus, CD19 and IL-10 were used to 
delineate B10 in the present study. Previous studies on regulatory 
B  cells used CD19 knockout mice, anti-CD20 antibody neu-
tralization, or IL-10 knockout mice (38). However, these methods 
influenced other B cell subsets or other IL-10-producing cells in 
addition to B10. CD22 was called inhibitory BCR co-receptors 
(39). Although some of other BCR co-receptors were expressed in 
other immune cell types such as dendritic cells, CD22 was domi-
nantly expressed on B cells (40). Study demonstrated that CD22 
FigUre 7 | insufficient il-10-producing B cells increases the Th17 response during 1,3-β-glucan-induced lung inflammation. Percentage of CD4+IL-
17A+ Th17 cells in the hilar lymph node was assayed by flow cytometry (a,B). Expressions of typical Th17 cytokine IL-17A (c), IL-23 (D), and its typical transcription 
factor ROR-γt (e) were assayed by real-time PCR (n = 5–6; *P < 0.05 compared with the saline group; #P < 0.05 compared with the glucan group).
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could regulate B cell through both ligand-dependent and ligand-
independent way (41). CD22 was considered to play an important 
role in regulating B  cells by binding to its ligand (42). Animal 
study confirmed that anti-CD22 antibody could preferentially 
deplete B10 in mice (34). It’s reasonable that CD22 engagement 
is particularly essential for B10 cells. Thus, anti-CD22 antibody 
was used in the current study to generate a B10 deficiency mouse 
model. Flow cytometry showed that anti-CD22 treatment limited 
B10 induction in mice after 1,3-β-glucan exposure. No obvious 
difference was observed between B10 percentage in saline group 
and B10 percentage in saline + anti-CD22 group. It’s reasonable 
to assume that anti-CD22 treatment contributed to deplete the 
inducible B10.
IL-10-producing B  cells (B10) have been characterized as a 
suppressive immune regulatory cell. Lack of B10 could amplify 
the allergic inflammation (43). In the present study, inadequate 
endogenous B10 led to intensive accumulation of inflammatory 
cells, including neutrophils, lymphocytes, and macrophages, 
which was similar to that in OVA-immunized mice (22). The exces-
sive inflammatory cells secreted overmuch pro-inflammatory 
cytokines, such as TNF-α and IL-6, which could further recruit 
much more inflammatory cells. Although TNF-α and IL-6 could 
be secreted by a variety of cells, such as activated macrophages, 
neutrophils, natural killer cells, T  cells, B  cells, fibroblast, etc. 
In this study, neutrophils, macrophages, and lymphocytes were 
three major contributors to the increase of TNF-α and IL-6. Since 
the most obvious changes of TNF-α and IL-6 were observed at 
day 1, when the changes of total cells were changed a lot. And the 
increase of TNF-α and IL-6 was not so significant when the changes 
of total cells showed no difference at day 7 and day 21. However, 
besides these three types, epithelial cells were also considered to 
be a source of these two pro-inflammatory cytokines. Insufficient 
B10 aggravated the inflammation, which was accompanied by 
the appearance of exacerbated inflammatory cells accumulation, 
prolonged inflammatory response, continual thickened alveoli 
septum, and severe destroyed alveolar structure. According to 
our dynamic observation on pathological changes, insufficient 
B10 influenced both the initiation and the development of lung 
inflammation. The suppressive function of B10 in lung inflam-
mation was also testified in other inflammatory diseases, such as 
asthma and enteritis (34).
Although the detail mechanism of how it participated in T cell 
immune responses is not clear, regulatory B cells were clarified 
to be associated with Th immune responses, either effector T cell 
responses or Treg response (36). In the current study, B10 exerted 
its regulatory function via inhibiting Th1/Th17 responses in 
early stage and suppressing Th2 response in late stage. Our study 
demonstrated that insufficient B10 amplified the Th1 response, 
according to the increased number of Th1 cells, elevated levels 
of Th1 cytokine IFN-γ, and the continued high level of Th1 
typical transcription factor T-bet. And this outcome was in 
accord with other studies (25, 44). On the other hand, T-bet is 
reported to be expressed in many cells of the adaptive and innate 
immune system, such as natural killer cells and dendritic cells, 
which might contribute to its continued high level at late time 
points. Transferring B10 to IL-10 knockout mice inhibited Th1 
response in arthritis (45). The proliferation of Th1 cells was not 
affected by B10 yet in vitro. Insufficient B10 played an uncertain 
role in affecting Th17 response. In the current study, anti-CD22 
treatment led to higher level of Th17 response. The negative 
FigUre 8 | insufficient il-10-producing B cells restricts the regulatory T cell (Treg) response during 1,3-β-glucan-induced lung inflammation.  
(a) The gating strategy of Treg in flow cytometry. Percentage of CD4+Foxp3+ Treg cells in the hilar lymph node was assayed by flow cytometry (B,c). Expressions of 
Treg functional molecules Foxp3 (D), CTLA-4 (e), inhibitory cytokines IL-10 (F), and TGF-β (g) were assayed by real-time PCR (n = 5–6; *P < 0.05 compared with 
the saline group; #P < 0.05 compared with the glucan group).
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correlation between B10 and Th17 response was also reported 
(46). Others believed that B10 could inhibit Th17 response only 
when Th1 response was absent (47). However, the role of B10 in 
influencing Th2 response is still debatable. Some studies believed 
that B10 could promote Th2 response, according to its regulation 
on Th1/Th2 balance. On the contrary, others illustrated that B10 
could control airway disease in Th2-predominant asthma mice 
(17). In our study, insufficient B10 increased the levels of Th2 
cytokines, IL-4 and IL-13. Insufficient B10 also increased Th2 
transcription factor GATA3, which might elevate the expressions 
of Th2 cytokines feedback. Taken together, B10 could suppress 
Th1, Th2, and Th17 responses to varying extent in different stage 
after 1,3-β-glucan exposure.
Previous studies already demonstrated that Treg could obvi-
ously regulate 1,3-β-glucan-induced lung inflammation (9, 10). 
Similarly, as a regulatory immune cell subset, whether the regula-
tion of B10 was associated with Treg? The present study showed 
that both B10 and Treg were significantly increased in lung 
inflammation, which indicated that B10 may also be involved in 
the induction of Treg after 1,3-β-glucan exposure. The increased 
B10 and Treg contributed to regulate the 1,3-β-glucan-induced 
lung inflammation as a result. However, not like the situation of 
saline group mice, B10 deficiency mice showed the overwhelm-
ing inflammation after 1,3-β-glucan exposure, which could not 
be controlled. It’s reasonable to hypothesize that Treg might be 
affected by two forces, inflammatory response and the number of 
B10. It seems that in this study, the influence of B10 was dominant, 
which may need further study to complete testified. Next, what’s 
the relationship between B10 and Treg? Some studies indicated 
that B10 could increase Treg accumulation through converting 
resting non-Treg into Treg (48, 49). Others believed that Treg 
could act independently and was not affected by B cell depletion 
(50). According to the current study, insufficient B10 could reduce 
the number of Treg, as well as the expressions of its typical tran-
scription factor Foxp3 and its functional molecular CTLA-4. Our 
study indicates that B10 exerted its suppressive function through 
promoting Treg response in 1,3-β-glucan-induced lung inflamma-
tion. Besides of Treg, B10 regulation was based on either cell–cell 
contact through surface molecules or by releasing cytokines (51). 
Insufficient B10 affected the levels of inhibitory cytokine IL-10 
and TGF-β during the late stage of 1,3-β-glucan-induced lung 
inflammation, which suggested that regulatory function of B10 
was associated with inhibitory cytokine IL-10.
In the opposite direction, whether Treg could also affected 
B10? Our study showed that the immune regulation caused 
by early Treg depletion was almost same as the effect resulted 
from insufficient B10. And depleting Treg before 1,3-β-glucan 
exposure decreased the number of B10. This might because 
FigUre 9 | regulatory T cell (Treg) depletion at the early stage after 1,3-β-glucan exposure could limit il-10-producing B cells (B10) and promotes 
inflammatory responses. Percentages of Treg cells and B10 in the hilar lymph node were assayed by flow cytometry (a). Expressions of Treg functional molecules 
Foxp3 (B) and CTLA-4 (c) were assayed by real-time PCR. Total cells, neutrophils, macrophages, and lymphocytes (D) in bronchoalveolar lavage fluid were counted 
using Giemsa staining. Expressions of TNF-α (e) and IL-6 (F) in lung were assayed by real-time PCR. Th1 response, including the percentage of Th1 cells (g), the 
expressions of IFN-γ (h), IL-2 (i), and T-bet (J) was checked by flow cytometry and real-time PCR. Th17 response, including the percentage of Th17 cells (K), the 
expressions of IL-17A (l), IL-23 (M), and ROR-γt (n) was checked by flow cytometry and real-time PCR (n = 5–6; #P < 0.05 compared with the glucan group).
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FigUre 11 | schematic representation of the role of B10 in 
modulating T helper (Th) immune responses after 1,3-β-glucan 
exposure in mice lung.
FigUre 10 | regulatory T cell (Treg) depletion at the late stage after 1,3-β-glucan exposure could not affect il-10-producing B cells (B10). 
Percentages of Treg cells and B10 in the hilar lymph node were assayed by flow cytometry (a). Expressions of Treg functional molecules Foxp3 (B), CTLA-4 (c), 
and inhibitory cytokine IL-10 (e) were assayed by real-time PCR. Secretion of inhibitory cytokine IL-10 (D) in BAL was assayed by cytomeric bead arrays. Total cells, 
neutrophils, macrophages, and lymphocytes (F) in bronchoalveolar lavage fluid were counted using Giemsa staining. Expressions of typical Th2 cytokine IL-13  
(g) and IL-4 (i) were check by real-time PCR. Secretions of typical Th2 cytokine IL-13 (h) and IL-4 (J) were check by real-time PCR (n = 5–6; #P < 0.05 compared 
with the glucan group).
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that Treg could help B10 activation through TLRs ligation (20). 
B10 and Treg homeostasis need interacted with each other (52). 
Whereas, depleting Treg at late stage after 1,3-β-glucan exposure 
was not capable to affect the number of B10. And its modulation 
on immune response was different from that caused by insuf-
ficient B10. This might attribute to that Treg depletion occurred 
after B10 activation, when B10 could be maintained by other 
cells or molecules (36). Thus, it could be seen that there was a 
dual relationship between B10 and Treg. These two regulatory 
subsets could coordinate with each other at the early stage of 
1,3-β-glucan-induced lung inflammation. However, at the late 
stage, the regulatory role of B10 was independent with Treg. 
As showed in Figure 11, our results indicated that B10 and the 
relationship between B10 and Treg might have potential from the 
perspective of inflammation treatment.
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